DSTN Variant 1: A Potential Drug Target for Cancer and Cellular Processes

Target Name: DSTN

NCBI ID: G11034

DSTN

DSTN Variant 1: A Potential Drug Target for Cancer and Cellular Processes

Drug Targets (DSTN) are molecules that are targeted by drugs to interact with specific proteins and contribute to the development of various diseases. DSTN variants have been identified and studied extensively, and some of these variants have been found to be potential drug targets. In this article, we will focus on DSTN variant 1, which has been shown to be a drug target in various cellular processes, including cell signaling, DNA replication, and apoptosis.

DSTN Variant 1: Structure and Function

DSTN (DSTN1) is a 21-kDa protein that is expressed in various tissues, including brain, heart, and pancreas. It is composed of a N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal protein domain. The transmembrane domain is responsible for the protein's maintainability, and the coiled-coil domain is responsible for the protein's stability and interaction with other proteins.

The DSTN1 protein has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and apoptosis. One of the most significant functions of DSTN1 is its role in cell signaling. DSTN1 has been shown to be involved in the regulation of neurotransmitter signaling, particularly in the regulation of dopamine signaling.

DSTN1 has also been shown to be involved in DNA replication. DSTN1 has been shown to play a role in the regulation of DNA replication, specifically in the initiation of DNA replication. DSTN1 has been shown to interact with the protein responsible for initiating DNA replication, called DNDC1, and to help DNDC1 to function properly.

In addition to its role in cell signaling and DNA replication, DSTN1 has also been shown to be involved in apoptosis. DSTN1 has been shown to play a role in the regulation of apoptosis, which is a natural process that helps the body to remove damaged or dysfunctional cells.

DSTN1 has been shown to interact with various proteins, including the protein Bcl-2. Bcl-2 is a protein that has been shown to play a role in the regulation of apoptosis, and DSTN1 has been shown to interact with Bcl-2 in a variety of cellular processes.

DSTN1 and Cancer

DSTN1 has been shown to be involved in the regulation of various cellular processes that are related to the development and progression of cancer. For example, DSTN1 has been shown to play a role in the regulation of cell proliferation, which is a critical process for the development of cancer.

In addition to its role in cell proliferation, DSTN1 has also been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. DSTN1 has been shown to play a role in the regulation of angiogenesis, which is a critical process for the development of cancer.

DSTN1 and Therapeutic Applications

DSTN1 has been shown to be a potential drug target in various diseases, including cancer. Because of its role in various cellular processes, DSTN1 has been shown to be a potential target for drugs that can inhibit its activity.

One of the most promising approaches to targeting DSTN1 is the use of small molecules. Small molecules can be used to inhibit the activity of DSTN1 and prevent it from interacting with its downstream targets. One of the small molecules that has been shown to be effective in inhibiting the activity of DSTN1 is called LY294012.

In addition to LY294012, a variety of other small molecules have also been shown to be effective in inhibiting the activity of DSTN1. These small molecules include inhibitors of the enzyme inhibitor protein (AP-1), which is

Protein Name: Destrin, Actin Depolymerizing Factor

Functions: Actin-depolymerizing protein. Severs actin filaments (F-actin) and binds to actin monomers (G-actin). Acts in a pH-independent manner

The "DSTN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DSTN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets